Book your seat

About

Susanne Michel MD, MSc

Co-founder

Ascenian Consulting, Germany

Susanne is a co-founder of Ascenian Consulting and responsible for Market Access and HTA. She has more than 11 years of experience of market access consulting and delivering measurable business results in new product development and repositioning products on the market. Typical projects include clinical trial assessment, payer positioning, value strategy, and pricing strategy. After working for the Ministry of Health in Berlin as senior adviser and followed by time at as a clinical trial assessor at IQWIG, Susanne joined the Department of Health in England where she was a strategy policy leader for six years when NICE was established and conducted clinical assessments at NICE. Susanne has worked for Pricewaterhouse Coopers in Luxembourg leading the Health Research Institute Europe and was responsible for the assessment of in licensing opportunities in cell and gene therapies. Susanne holds a medical degree and a Masters in Strategy from London School of Economics and Political Science. Susanne is located in Paris and Berlin.

Noemi-Muszbek_400x400_

Noemi Muszbek MSc

Health Economics Director, Partner

Visible Analytics, UK

Noemi is Director of Health Economics at Visible Analytics, based in Reading, UK. Previously, she was Senior Research Leader in the Modelling and Simulation group of Evidera for 13 years, and prior to that Health Economics Manager at Astra Zeneca for five years. Noemi has led multiple programs of work, that had various components including economic models, literature reviews, indirect comparisons, trial analyses, utility studies, retrospective database analyses, physician surveys, payer research and reimbursement submissions. She has worked on cost-effectiveness and budget impact models (cohort and patient level simulation models), for different purposes (reimbursement submissions, internal decision making, evidence generation planning, publications). She has prepared white papers in different policy issues and have taken part in guideline development for economic evaluation and for reimbursement process. Noemi has prepared and led submissions for multiple agencies, including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) in the UK, the Norwegian Medicines Agency (NoMA), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Canadian Agency for Drugs and Technologies in Health (CADTH). Noemi holds a Master’s degree in Health Economics from the University of York, UK and one in Public Economics from the Corvinus University (then Budapest University of Economic Sciences, Hungary), and a Bachelor of Science degree in Economics.Noemi has presented studies at international clinical and health economic conferences and she has published numerous articles in journals such as Pharmacoeconomics, Clinical Therapeutics, Current Medical Research and Opinion, Blood Pressure and Health Policy. She co-chairs the Oncology Modelling Working Group at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and is a member of the European Society for Medical Oncology (ESMO).

Edit-Remak_400x400_

Edit Remak MSc, PhD

Health Economics Director, Partner

Visible Analytics, Hungary

Edit has joined Visible Analytics as Director of Health Economics based in Budapest, Hungary. Previously she was a Senior Research Leader in the Modelling and Simulation group Evidera
for over 17 years. Edit ‘s main areas of interest are quantitative decision analysis and modeling. She has experience in developing different model types (cohort and patient level simulation models), serving different aims (cost-effectiveness models, budget impact models, pricing models), for different audiences (regulatory bodies, expert communities, internal decision makers). Edit has been involved in the preparation of a number of evidence submissions for the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the National Centre for Pharmacoeconomics (NCPE) in Ireland, the Tandvårds- och Läkenedelsförmånsverket (TLV) in Sweden and similar bodies in other countries. She has also coordinated multinational studies, prepared manuscripts, and training for pharmaceutical companies in the use and interpretation of models for cost effectiveness. Edit completed a PhD in Health Economics in 2015 at Brunel University and and MSc in Health Economics at the University of York. She was awarded Best New Investigator Podium Presentation by ISPOR In 2002. She has extensively published in journals such as the Journal of Clinical Oncology, European Journal of Health Economics, British Journal of Cancer, and Journal of Medical Economics.